NCT01672151

Efficacy of Rapamycin Therapy With Chronic Immune Thrombocytopenia

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 35 (actual)
• Sponsor: First Affiliated Hospital of Suzhou Medical College · Academic / Other
• Sex: All
• Age: —
• Healthy volunteers: Accepted

Summary

The aim of our study is to evaluate the efficacy of rapamycin with Refractory Immune Thrombocytopenic Purpura (RITP) and explore the further mechanism.

Detailed description

Rapamycin, an immunosuppressive drug, is widely used to prevent allograft rejection and autoimmune diseases. Many studies have shown that the drug contributes to the expansion of regulatory T cells and preserves the highly suppressive function of autoreactive T cells. Patients with RITP often display a decreased proportion of regulatory T cells by flow cytometer, therefore, the investigators will examine the efficacy of rapamycin in RITP patients.

Conditions

• Immune Thrombocytopenic Purpura

Interventions

Type	Name	Description
DRUG	rapamycin	4mg oral administration on the first day, 2 mg/d oral administration for 3 months

Timeline

• Start date: 2011-11-01
• Primary completion: 2012-08-01
• Completion: 2012-08-01
• First posted: 2012-08-24
• Last updated: 2012-08-24

Locations

1 site across 1 country: China